Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS.NS)
INR 50.32
(4.77%)
INR 50.32
(4.77%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 297.57 Million INR | -19.6% |
| 2022 | 370.12 Million INR | 164.93% |
| 2021 | 139.7 Million INR | -19.62% |
| 2020 | 173.8 Million INR | -0.11% |
| 2019 | 174 Million INR | 10.06% |
| 2018 | 158.09 Million INR | 482.89% |
| 2017 | 27.12 Million INR | -71.01% |
| 2016 | 93.54 Million INR | -27.56% |
| 2015 | 129.13 Million INR | 19.04% |
| 2014 | 108.48 Million INR | 122.9% |
| 2013 | 48.66 Million INR | 11.85% |
| 2012 | 43.51 Million INR | 32.3% |
| 2011 | 32.88 Million INR | 12.82% |
| 2010 | 29.15 Million INR | -34.82% |
| 2009 | 44.72 Million INR | 303.97% |
| 2008 | 11.07 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | 11.23 Million INR | -96.96% |
| 2023 FY | 297.57 Million INR | -19.6% |
| 2023 Q2 | 362.06 Million INR | 3121.82% |
| 2023 Q3 | 74.55 Million INR | -79.41% |
| 2023 Q4 | 297.57 Million INR | 299.14% |
| 2022 Q1 | 1.91 Million INR | -98.63% |
| 2022 FY | 370.12 Million INR | 164.93% |
| 2022 Q4 | 370.12 Million INR | 29676.59% |
| 2022 Q3 | 1.24 Million INR | -99.48% |
| 2022 Q2 | 240.92 Million INR | 12454.51% |
| 2021 Q2 | 225.21 Million INR | 3366.46% |
| 2021 Q4 | 139.7 Million INR | 11830.47% |
| 2021 Q1 | 6.49 Million INR | -96.26% |
| 2021 Q3 | 1.17 Million INR | -99.48% |
| 2021 FY | 139.7 Million INR | -19.62% |
| 2020 FY | 173.8 Million INR | -0.11% |
| 2020 Q1 | 5.02 Million INR | -97.11% |
| 2020 Q2 | 127.96 Million INR | 2445.37% |
| 2020 Q4 | 173.8 Million INR | 0.0% |
| 2019 Q3 | 3.3 Million INR | -98.08% |
| 2019 FY | 174 Million INR | 10.06% |
| 2019 Q4 | 174 Million INR | 5166.42% |
| 2019 Q1 | 3.68 Million INR | -97.67% |
| 2019 Q2 | 171.82 Million INR | 4559.84% |
| 2018 FY | 158.09 Million INR | 482.89% |
| 2018 Q1 | 60.08 Million INR | 4008.31% |
| 2018 Q4 | 158.09 Million INR | 0.0% |
| 2017 Q4 | -1.53 Million INR | -101.15% |
| 2017 FY | 27.12 Million INR | -71.01% |
| 2017 Q3 | 133.65 Million INR | 0.0% |
| 2016 Q4 | 93.54 Million INR | 0.0% |
| 2016 FY | 93.54 Million INR | -27.56% |
| 2015 FY | 129.13 Million INR | 19.04% |
| 2015 Q4 | 129.13 Million INR | 0.0% |
| 2014 FY | 108.48 Million INR | 122.9% |
| 2014 Q4 | 108.48 Million INR | 0.0% |
| 2013 FY | 48.66 Million INR | 11.85% |
| 2013 Q4 | 48.66 Million INR | 0.0% |
| 2012 FY | 43.51 Million INR | 32.3% |
| 2012 Q4 | 43.51 Million INR | 0.0% |
| 2011 Q4 | 32.88 Million INR | 0.0% |
| 2011 FY | 32.88 Million INR | 12.82% |
| 2010 FY | 29.15 Million INR | -34.82% |
| 2009 FY | 44.72 Million INR | 303.97% |
| 2008 FY | 11.07 Million INR | 0.0% |
| 2008 Q4 | 11.07 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 92.302% |
| Hester Biosciences Limited | 2.29 Billion INR | 87.009% |
| Aarti Drugs Limited | 5.54 Billion INR | 94.637% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 88.607% |
| Albert David Limited | -278.36 Million INR | 206.901% |
| Alembic Limited | 66.9 Million INR | -344.812% |
| Alkem Laboratories Limited | -1.6 Billion INR | 118.49% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | -29.42% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 90.98% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 1713.245% |
| Brooks Laboratories Limited | 49.48 Million INR | -501.352% |
| Eris Lifesciences Limited | 13.8 Billion INR | 97.845% |
| FDC Limited | -57.75 Million INR | 615.271% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 110.468% |
| Gufic Biosciences Limited | 3.19 Billion INR | 90.684% |
| Hikal Limited | 7.96 Billion INR | 96.265% |
| Ind-Swift Limited | 9.5 Billion INR | 96.87% |
| Innova Captab Limited | 2.33 Billion INR | 87.249% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 127.021% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 121.41% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 98.901% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | 333.143% |
| Lupin Limited | 19.38 Billion INR | 98.465% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 69.504% |
| Medico Remedies Limited | 78.67 Million INR | -278.229% |
| Morepen Laboratories Limited | -231.17 Million INR | 228.725% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 95.167% |
| Orchid Pharma Limited | -1.31 Billion INR | 122.649% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 112.674% |
| RPG Life Sciences Limited | -364.7 Million INR | 181.596% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -147.902% |
| Sigachi Industries Limited | 859.94 Million INR | 65.396% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 97.034% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -105.261% |
| Themis Medicare Limited | 764.96 Million INR | 61.099% |
| Unichem Laboratories Limited | 931.91 Million INR | 68.068% |
| Vaishali Pharma Limited | 119.13 Million INR | -149.783% |
| Wanbury Limited | 1.1 Billion INR | 73.091% |
| Windlas Biotech Limited | -273.04 Million INR | 208.987% |
| ZIM Laboratories Limited | 983.6 Million INR | 69.746% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 107.165% |
| Ipca Laboratories Limited | 11.41 Billion INR | 97.393% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 100.411% |
| Venus Remedies Limited | -267.7 Million INR | 211.161% |
| Sakar Healthcare Limited | 790.93 Million INR | 62.376% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 91.943% |
| Divi's Laboratories Limited | -39.77 Billion INR | 100.748% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 105.937% |
| Mankind Pharma Limited | -1.74 Billion INR | 117.021% |
| Sequent Scientific Limited | 4.17 Billion INR | 92.879% |
| Laurus Labs Limited | 24.35 Billion INR | 98.778% |
| Neuland Laboratories Limited | -214.05 Million INR | 239.018% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 89.452% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 106.944% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 92.393% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 219.61% |
| Wockhardt Limited | 18.27 Billion INR | 98.371% |
| Bal Pharma Limited | 1.26 Billion INR | 76.449% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 97.696% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 125.703% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | 181.186% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 105.403% |
| Shilpa Medicare Limited | 9.06 Billion INR | 96.719% |
| Valiant Laboratories Limited | 649.9 Million INR | 54.212% |
| Ajanta Pharma Limited | -954.9 Million INR | 131.163% |
| Granules India Limited | 9.28 Billion INR | 96.796% |
| Medicamen Biotech Limited | 160.31 Million INR | -85.62% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -543.958% |
| Piramal Enterprises Limited | 491.39 Billion INR | 99.939% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 99.065% |
| NATCO Pharma Limited | -5.81 Billion INR | 105.116% |
| Suven Life Sciences Limited | -1.63 Billion INR | 118.226% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 84.605% |
| Strides Pharma Science Limited | 23.25 Billion INR | 98.72% |
| Indoco Remedies Limited | 6.47 Billion INR | 95.405% |
| Alpa Laboratories Limited | 35.36 Million INR | -741.499% |
| Lasa Supergenerics Limited | 205.79 Million INR | -44.597% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 131.597% |